Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

MEN1703

PIM and FLT3 inhibitor

ONCOLOGY

CURRENT DEVELOPMENT PHASE: AML / ACUTE MYELOID LEUKAEMIA

preclinicl
phase i
phase ii
phase iii
registration
post-registration

MEN1703 is a first-in-class orally available dual PIM and FLT3 kinase inhibitor discovered by Selvita (now Ryvu Therapeutics) and acquired by the Menarini Group at the beginning of 2017.

The molecule has a unique activity profile for its ability of inhibiting both PIM kinase, important for cell cycle regulation, cell survival and tumorigenesis, and FLT3, a kinase involved in the onset and progression of acute myeloid leukemia (AML).

None of the molecules currently in clinical development has this dual activity.

The multicenter, Phase I/II clinical trial DIAMOND-01 is currently ongoing in patients with relapsed /refractory AML.

VISIT OUR CLINICAL TRIALS DATABASE


THERAPEUTIC AREAS

Discover all of Menarini's products marketed in Italy. Read More »

DIAGNOSTICS

 

Advanced Technology

READ MORE »

THE MENARINI GROUP

Discover the leading Italian pharmaceutical company in the world. Read More »

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more